Tridek-One
Entity

  • Tridek-One

    Created in 2018
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    20 555

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    4 Rue Thénard, 75005 Paris, France

    Paris

    France

  • Employees

    Scale: 2-10

    Estimated: 16

  • SIREN

    840361315

  • Engaged corporates

    0
    0 0

  • Added in Motherbase

    1 year, 10 months ago
Description
  • Value proposition

    We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

    Tridek-One is a spin-off from Inserm that develops first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases.

    The company primarily focuses on the research and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance.
    Anti-CD31 agonistic mAbs have the potential to provide targeted immunomodulatory activity with a favorable safety profile in diseases with high unmet clinical need.

    Tridek-One has initiated a discovery program which targets another ITIM receptor, fully leveraging its understanding of inhibitory checkpoint receptor modulation and agonistic monoclonal antibodies engineering.

    Our company is financed by leading European investors and led by an experienced management team.

    Santé, Healthcare, Immunomodulation, monoclonal antibody, vasculatis, and ANCA

  • Original language

    We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

    Founded in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti, researchers in INSERM Unit 1148, located at Bichat Hospital in Paris, with the support of the funds Advent France Biotechnology, Tridek-One is developing a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions. Tridek-One has announced a 3M€ funding supported by two venture funds, Advent France Biotechnology and Advent Life Sciences (UK).

  • Home - Tridek One

    Tridek-One is a private biotechnology company founded in 2018, based on groundbreaking research by our scientific founders at INSERM, Paris on the role of CD31 in the modulation of the immune response.

    • https://www.tridekone.com/
Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Last news
Show all articles
Social network dynamics